Objectives: To measure the relationship between randomized controlled trial (RCT) efficacy and real-world effectiveness for oncology treatments as well as how this relationship varies depending on an RCT's use of surrogate versus overall survival (OS) endpoints. Methods: We abstracted treatment efficacy measures from 21 phase III RCTs reporting OS and either progression-free survival or time to progression endpoints in breast, colorectal, lung, ovarian, and pancreatic cancers. For these treatments, we estimated real-world OS as the mortality hazard ratio (RW MHR) among patients meeting RCT inclusion criteria in Surveillance and Epidemiology End ResultsMedicare data. The primary outcome variable was real-world OS observed in the Surveillance and Epidemiology End Results-Medicare data. We used a Cox proportional hazard regression model to calibrate the differences between RW MHR and the hazard ratios on the basis of RCTs using either OS (RCT MHR) or progression-free survival/time to progression surrogate (RCT surrogate hazard ratio [SHR]) endpoints. Results: Treatment arm therapies reduced mortality in RCTs relative to controls (average RCT MHR ¼ 0.85; range 0.56-1.10) and lowered progression (average RCT SHR ¼ 0.73; range 0.43-1.03). Among real-world patients who used either the treatment or the control arm regimens evaluated in the relevant RCT, RW MHRs were 0.6% (95% confidence interval À3.5% to 4.8%) higher than RCT MHRs, and RW MHRs were 15.7% (95% confidence interval 11.0% to 20.5%) higher than RCT SHRs. Conclusions: Real-world OS treatment benefits were similar to those observed in RCTs based on OS endpoints, but were 16% less than RCT efficacy estimates based on surrogate endpoints. These results, however, varied by tumor and line of therapy.
Introduction
Two-third of cancer drugs are approved on the basis of surrogate endpoints such as progression-free survival (PFS) or time to progression (TTP) measured in randomized controlled trials (RCTs) [1] . In real-world practice, however, clinicians selecting treatments regularly face the challenge of translating surrogate and overall survival (OS) benefits from RCTs into expectations about real-world OS benefits for their patients.
Efforts are underway to help physicians better approach this problem. One example is the American Society of Clinical Oncology's (ASCO's) value framework, which aims to help physicians and patients select preferred therapies [2] . The most salient feature of its "net health benefit" metric is the clinical benefit component, which depends largely on the hazard ratio (HR) measured in RCTs. In the May 2016 revised version of ASCO's value framework, the clinical benefit component assigns a 0.8 adjustment factor (i.e., 20% reduction in points) to RCTs with surrogate endpoints-such as PFS-compared with RCTs with OS endpoints [3] . In other words, the ASCO framework assumes that real-world mortality reductions are 20% smaller in magnitude relative to the reduction in PFS reported in an RCT.
The fundamental question for clinical and payer decision making is how treatment efficacy measured in clinical trials translates into real-world effectiveness. Most evidence on this relationship relies on comparisons of surrogate and nonsurrogate endpoints within trials themselves as opposed to comparisons with real-world OS [1, [4] [5] [6] [7] [8] [9] . In this study, we examined the relationship between reported RCT efficacy and real-world effectiveness for oncology treatments and examined whether this relationship varies by RCT endpoint (OS vs. surrogate measures such as PFS or TTP). Using trial endpoints from RCTs of patients with breast, colon, lung, ovarian, and pancreatic cancer, we estimated a real-world percentage adjustment that would translate RCT efficacy into real-world effectiveness and allowed this adjustment factor to vary by the type of trial endpoint. This study proposes an evidence-based adjustment factor that could be used by ASCO's value framework to ensure that physicians are delivering accurate guidance to patients, and it also provides ASCO with a method for refining and expanding its framework in the future by incorporating fast-evolving real-world data sources.
Methods

Data Sources
We reviewed the National Comprehensive Cancer Network Treatment Guidelines [10] and the National Cancer Institute's list of approved cancer drugs [11] to identify treatments used across five tumor sites (breast, colorectal, lung, ovarian, and pancreatic cancers). These tumor sites were selected because they ranked among the top 10 in terms of US incidence rates [12] and had three or more treatments approved by the US Food and Drug Administration (FDA) before 2009. For each of the identified treatments, we reviewed the treatment's FDA label and included only those regimens with phase III pivotal trials reporting both OS and either PFS or TTP. Treatment regimens were also restricted to those approved by the FDA before 2009 to ensure that patients had at least 2 years of real world survival data were available in Surveillance and Epidemiology End Results (SEER)-Medicare. We We calculated real-world OS using 1991 to 2010 SEER-Medicare data from all available registries. The SEER-Medicare database links data from the National Cancer Institute's SEER registry to the corresponding health insurance claims of Medicare beneficiaries [12] . The SEER data are drawn from large, populationbased cancer registries that collect clinical data at the time of tumor diagnosis-such as tumor site, cancer stage, and (if applicable) tumor size-along with an eventual death date and cause of death for patients whose death was observed before the latest available year of data. The Medicare claims data contain a comprehensive history of health care utilization from the date of Medicare enrollment through patient death. Linked SEERMedicare data provide a unique population-based source of information that has been used to investigate longitudinal cancer outcomes such as racial differences in survival [13] , to develop case-control studies [14] , and to determine the real-world effectiveness of cancer therapies [15] .
Inclusion and Exclusion Criteria
From SEER-Medicare, we selected patients with a primary diagnosis for breast, colorectal, lung, ovarian, or pancreatic cancer. To control for differences between clinical trial and real-world patients, we retained only the subset of patients who met inclusion and exclusion criteria of the corresponding pivotal trial of the treatment regimen received in the real world. Specifically, we applied the inclusion and exclusion criteria related to patient age, sex, cancer histology and stage, presence of other cancers, and other comorbidities. Finally, patients were required to have initiated cancer treatment within 90 days of diagnosis. This group of patients-which we defined as the "baseline" cohort-represented real-world patients who were similar to patients eligible to participate in the RCT corresponding to the real-world treatment they used. Patients appeared in the sample multiple times if they received more than one of the treatments of interest. We included only those treatments that had 10 or more observations in the SEER-Medicare data for both the treatment and the control arm regimens.
SEER-Medicare patients were assigned to a treatment or a comparator arm on the basis of their tumor, the combinations of therapies received, and line of therapy. To be assigned to one of the real-world comparator arms, patients were required to have received the exact comparator regimen outlined in the relevant RCT. In the case of combination treatments, we required that patients use all treatments in the combination within 30 days of the first date on which any treatment in the combination was used [16] . First-line therapy was defined by any anticancer treatment that was initiated within 3 months of diagnosis; second-line (third-line) therapy was defined as the first claim of any anticancer treatment occurring after a 45-day clean period since the last claim of a treatment in the first-line (second-line) regimen [16] .
To mitigate selection bias due to nonrandom receipt of treatment in the real world, we excluded patients assigned to comparator arms if they received the comparator treatment after the date of the relevant new therapy launch. (See the Methods section in Supplemental Materials found at http://dx.doi.org/10. 1016/j.jval.2017.04.003 for a description on how this approach mitigates selection bias.) This approach eliminated patients from the sample whose physician nonrandomly treated them with the comparator therapy, even though the novel treatment was available. We also included only those patients who were diagnosed with cancer for 5 years or less before or after the treatment arm regimen had been approved by the FDA to account for the fact that cancer survival generally improves over time.
Statistical Analysis
Real-world OS for each patient was measured as the time between each patient's first treatment with the treatment combination of interest and death. Treatment initiation dates were identified in Medicare claims data and death dates were identified from SEER. Data for patients who survived beyond the data collection time frame were censored on the basis of the last month of available data (December 2010). Clinical trial efficacy was measured using phase III trial data reporting OS and surrogate (i.e., either PFS or TTP) endpoints. Clinical trial HRs for both OS and PFS/TTP were obtained from the literature. When HRs were not directly available, we assumed that the survival cumulative density function followed an exponential distribution and that the hazard rate was constant over time, and estimated the HR as the ratio between median OS (or surrogate endpoint) in the treatment arm and the median OS (or surrogate endpoint) in the control arm [17] . All statistical analyses were performed using Stata version 14.1 (StataCorp, College Station, TX).
We performed a Cox proportional hazards regression analysis to determine whether real-world treatment effectiveness in SEER-Medicare data as measured by OS was predicted by treatment efficacies from phase III RCTs based on either OS or surrogate endpoints (PFS/TTP). Separate analyses were performed using trial OS end points and trial surrogate endpoints as predictors in the regression analyses. The outcome variable in the analyses was real-world OS in SEER-Medicare data. We controlled for patient age, sex, and cancer stage. For persons in the treatment arm, we included an offset term, which was either the RCT OS or RCT surrogate hazard ratios (RCT SHRs) (Stata command: stcox, offset). The primary independent variable was an indicator variable that indicated whether the patient received the treatment or control regimen. The regression coefficient (b) for that indicator variable was used to calculate the percentage difference (f) between real-world mortality hazard ratios
(RW MHRs) and clinical trial hazard ratios (RCT HRs), and was calculated from the equation f ¼ 100 Â (RW MHR À RCT HR)/RCT HR ¼ (exp(b) À 1) Â 100 (for more details, see the Methods section in Supplemental Materials).
For example, suppose the RCT MHR is 0.75, which indicates a 25% reduction in risk of mortality with the treatment. If the RW MHR is only 0.90, then the percent difference in the HRs is f ¼ 100 Â (0.9 À 0.75)/0.75 ¼ 20%. The interpretation in this example is that the RCT MHR overestimates treatment effectiveness on mortality in the real world by 20%.
We conducted a series of sensitivity analyses. First, although our baseline cohort limited the patient population to those who met the RCT inclusion and exclusion criteria, we also examined the full cohort, which we defined as all patients receiving the relevant treatment in SEER-Medicare for a given tumor site and line of therapy. Second, we examined how the relationship between treatment efficacy and effectiveness varied by cancer site, line of therapy, number of patients enrolled in the RCT, and RCT geographic location. Third, we tested how sensitive our results were to 1) removing repeated observations when patient receives treatment for a different line of therapy, 2) limiting the analysis to patients aged 65 years and older, 3) including SEER registry fixed effects, 4) including patients in the analytic sample who received the treatment in the control arm after the approval of the anticancer therapy in the trial's treatment arm, 5) reestimating the value of f after excluding cases in which the trial HR was estimated as the ratio of median OS or PFS. Fourth, we conducted a series of tests to examine whether the Cox proportional hazard assumption is violated.
We also compared the ASCO framework valuations to our empirically derived valuations for RCTs with PFS/TTP endpoints.
Results
After applying the inclusion and exclusion criteria to 1,887,800 patients in the SEER-Medicare database, we were left with 97,401 tumor-treatment-patient observations (71,844 unique patients) that were included in the full cohort specification across 21 RCTs of interest for 18 unique treatment combinations. After applying the inclusion and exclusion criteria from each relevant RCT for our baseline cohort, we were left with 21,811 tumortreatment-patient observations (18,148 unique patients) ( Table 1) . Eight of the 29 RCTs identified in the literature were excluded from the analysis because 10 or fewer patients were observed to receive either the treatment or control arm regimen in SEERMedicare.
The baseline cohort included primarily elderly patients with average age at treatment being more than 70 years across all five tumors. Overall, about four out of every five patients were white and more than half of the patients had stage IV cancer at diagnosis. Average survival time from treatment-not accounting for censoring-varied across type of cancer, with the longest survival observed for breast cancer (30.7 months) and the shortest for pancreatic cancer (5.7 months). Patients in SEER-Medicare of the relevant tumor type who took the treatment or control arm regimen of interest were older than those in RCTs (Table 2 ). In 5 of 20 simulated trials in SEER-Medicare, there were more than 10 percentage points more females than in the corresponding RCT (1 RCT did not report the sex of the patient).
Treatment arm efficacy relative to control arm as measured in RCTs using SHRs based on PFS/TTP endpoints was generally lower (i.e., reduced mortality or progression) compared with efficacy measured using MHR (OS). Across all 21 RCTs, treatment arm therapies decreased progression (average SHR ¼ 0.73, minimum SHR ¼ 0.47, maximum SHR ¼ 1.03) and mortality (average MHR ¼ 0.83, minimum MHR ¼ 0.56, maximum MHR ¼ 1.04) ( Table 3) .
Real-world effectiveness was similar to treatment efficacy when trials used OS endpoints, but it was somewhat lower than trial efficacy when trials used surrogate endpoints. Real-world MHRs were not different from RCT MHRs (the percent difference was f ¼ 0.6%; 95% confidence interval [CI] À3.5% to 4.8%), whereas RW MHRs were significantly higher than RCT SHRs (the percent difference was f ¼ 15.7%; 95% CI 11.0% to 20.5%). In other words, if an RCT uses OS endpoints, one can expect real-world effectiveness to be similar among patients who would have qualified for the trial. If an RCT, however, measures efficacy by a surrogate PFS/TTP endpoint, one can expect real-world effectiveness as measured by OS to be about 16% lower than the surrogate benefit from the trial (Fig. 1) .
Treatments were predicted to be less effective when measured among all real-world patients who received the treatment compared with only those patients who would have been eligible for the clinical trial. In the full cohort that included patients even if they did not meet the RCT's inclusion and exclusion criteria, RW MHRs were 8.2% higher (95% CI 5.7%-10.8%) than RCT MHRs, and RW MHRs were 24.9% higher (95% CI 22.0%-28.0%) than RCT SHRs.
The correspondence between real-world and RCT outcomes varied with trial and tumor characteristics (see Appendix Table 1 in Supplemental Materials found at http://dx.doi.org/10.1016/j. jval.2017.04.003). Real-world MHRs were generally more likely to be similar to RCT HRs (i.e., either MHR or SHR) when patient expected survival was shorter, trial sample sizes were larger, or when the RCT of interest was conducted in the United States. For instance, RW MHRs were just 6.8% (95% CI 1.0%-12.9%) higher than RCT SHRs among patients receiving second-line treatment, but 28.1% (95% CI 20.4%-36.4%) higher for patients receiving firstline treatment. Among the full cohort of individuals who received treatments of interest, tumors with shorter expected survival (e.g., pancreas and lung) exhibited RW MHRs more similar to both RCT MHR and RCT SHR compared with tumors with longer survival (e.g., breast, colorectal, and ovary). These general findings were less apparent within our baseline cohort, perhaps because of the smaller sample size when we stratified the analysis by tumor type. Finally, real-world effectiveness was more likely to be similar to RCT efficacy when RCT sample sizes were larger or when the trial was conducted in the United States.
A series of sensitivity analyses sheded additional light on the robustness of these findings. We found that excluding patients who appeared multiple times because of receiving different eligible lines of therapy, excluding individuals younger than 65 years, or including SEER registry fixed effects (see Appendix  Tables 2, 3 and 4 in Supplemental Materials found at http://dx. doi.org/10.1016/j.jval.2017.04.003) had a small quantitative effect on the baseline results. Excluding trials in which RCT MHR and SHR were estimated on the basis of the ratio of median OS and PFS had a modest effect only on the OS adjustment factor (see Appendix Table 5 in Supplemental Materials found at http://dx. doi.org/10.1016/j.jval.2017.04.003). Nevertheless, including individuals who used the control arm therapy after the FDA approval date of the treatment regimen increased the adjustment factor by about 20 percentage points (see Appendix Table 6 in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval. 2017.04.003). Nevertheless, as we describe in more detail in the Methods section in Supplemental Materials, this finding likely indicates the presence of selection bias once both the treatment and control arm regimens are available to patients. Finally, when we tested whether the assumption of proportional hazards holds, we found mixed evidence. We observed that the proportional hazard assumption is violated using a linear time trend, but not when using the log of time in months (see Appendix Table 7 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval. 2017.04.003). In short, when the follow-up was less than 14 months (PFS) or 13 months (OS), the HR with the time interaction was less than our baseline model; after this threshold, the HR was greater.
We evaluated how our empirical findings compare with the assumptions of the ASCO value framework. For example, suppose an RCT indicates that the RCT SHR ¼ 0.70; the ASCO framework suggests assigning a value of [(1 À 0.70) Â 0.8] Â 100 ¼ 24, whereas our empirical analysis suggests assigning a value of Figure 2 compares the relationships between the RCT SHR and the valuations using both the ASCO guideline and our empirical findings. Compared with our empirically derived scores, the ASCO framework assigns higher scores to treatments with modest PFS improvements (RCT SHR 40.56), but lower scores for those treatments with larger PFS improvements (RCT SHR r0.56). When we examined the difference between the empirically derived scores and the ASCO framework scores, there was no statistically significant difference in 5 out of 21 cases, a small difference (o10 points) Note. The exclusion criteria were applied sequentially. The full cohort has 71,844 unique individuals and the baseline cohort comprises 18,148 unique individuals. The full cohort includes patients with the relevant tumor who received the treatment of interest. Controls who received treatment after new drug launch were excluded, because their disease prognosis are likely not comparable with the treatment arm. The baseline cohort includes patients with the relevant tumor who received the treatment of interest and met the inclusion/exclusion criteria of the relevant clinical trial. FFS, Fee-for-service; SEER, Surveillance and Epidemiology End Results. * Individuals paired with treatments may be assigned to more than one of the comparator arms (e.g., commonly prescribed therapy in the comparator arm). Note. The last column lists the references from which the RCT data were drawn. RCT, randomized controlled trial; SEER, Surveillance and Epidemiology End Results. * Line of therapy matching occurred on the basis of the lowest line of therapy reported in the RCT. † SEER-Tx means that patients in SEER-Medicare received the treatment of interest from the RCT treatment arm; SEER control means that patients received the treatment in the RCT control arm. ‡ Composition of stage at treatment of patients with locally recurrent or metastatic disease is not reported or clearly defined. § Indicates mean age because the median is not available. || Median or mean age not reported, but 44% of patients were older than 65 years.
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¶ 15% of patients were older than 70 years. # Reference does not report age.
** Eligibility criterion indicates recurrent or metastatic disease; stage is reported only on the basis of stage at diagnosis. Note. Median PFS, median TTP, and OS come from phase III clinical trial data. The last column lists the references from which the RCT data were drawn. HR, hazard ratio; MHR, mortality hazard ratio based on OS outcomes obtained from trials; OS, overall survival; PFS, progression-free survival; RCT, randomized controlled trial; SHR, surrogate hazard ratio based on surrogate (i.e., PFS or TTP) outcomes obtained from trials; TTP, time to progression. * Indicates TTP data obtained from trials. † Indicates PFS data obtained from trials. ‡ For 8 of 21 trials, HRs were calculated on the basis of reported PFS/TTP/OS in months because HRs were not available.
in 12 of 21 cases, and a large difference (410 points) in 4 cases. If we use tumor-specific factors, f, then in most cases (11 of 21) the results using the empirical and ASCO frameworks were not statistically different (not shown).
Discussion
Across 21 clinical trials of breast, colon, lung, ovarian, and pancreatic cancer treatments between 1991 and 2010, we found that real-world OS associated with these treatments was comparable with OS benefits estimated in RCTs. Real-world OS effectiveness was, however, 16% lower than RCT efficacy estimates based on surrogate endpoints. This finding suggests that in the five tumors studied, RCT surrogate endpoints should be discounted by approximately this amount when attempting to forecast real-world OS benefits. In addition, among trials using an OS endpoint, those with larger sample sizes and later lines of therapy were more likely to reliably predict real-world OS outcomes. Nevertheless, a larger discount would apply when Model controls for patient age at treatment, sex, and cancer stage. Adjustment factor ƒ 4 1 indicates that real-world treatment effectiveness is inferior to measured RCT efficacy because of a higher mortality rate; adjustment factor ƒ o 1 indicates that real-world treatment effectiveness is superior to RCT efficacy because of a lower mortality rate. CI, confidence interval; OS, overall survival; PFS, progression-free survival, RCT, randomized controlled trial; TTP, time to progression.
considering how an RCT outcome would apply to a broader realworld patient population, which may include patients who would not have met the RCT's inclusion and exclusion criteria. Several previous studies have examined the relationship between surrogate endpoints (PFS/TTP) and OS within trials themselves (i.e., analyzing whether OS is correlated with surrogate endpoints within trials that report both outcomes), with most demonstrating that surrogate measures are positively but imperfectly correlated with OS [1, [4] [5] [6] [7] [8] [9] . Fewer studies have examined how trial outcomes compare with survival benefits in real-world patients, but most of these studies are limited to a single therapy or cancer type [39] [40] [41] [42] or examine only OS outcomes [43] . To our knowledge, this study is the first to examine the relationship between real-world OS and OS and surrogate efficacy in clinical trials encompassing multiple tumor types and treatments. Our findings suggest that despite differences in patient populations between clinical trials and real-world settings, greater monitoring of patients in clinical trials, and concerns about crossover contamination and patient attrition in clinical trials, real-world and clinical trial OS correlate strongly.
The results of this article could be used in various ways. First, ASCO could alter its framework to use the parameter f calculated in this study to ensure that its value framework results are empirically grounded. Second, this study provides a general framework for estimating how surrogate endpoints are likely to translate into real-world improvements in OS. ASCO or other researchers could estimate the relevant discount factor for alternative patient populations (e.g., patient tumor site) and trial endpoint type (e.g., PFS, immune-related response rate, duration of response, and disease control rate). As new realworld data sources emerge from both private companies (e.g., CancerLinQ, Flatiron Health, IBM, IMS, Optum, and NantHealth) and nonprofit organizations (Patient-Centered Outcomes Research Institute via PCORnet) [44] , this method can be applied to an increasing number of real-world databases. Third, this study could help inform trial design with respect to endpoint selection. Admittedly, the choice of endpoints in a trial is a complex question that extends far beyond the confines of this study. Nevertheless, it provides new evidence to help clinicians understand under what circumstances trial data may generalize to the real world.
This study has several limitations. First, our treatment effectiveness estimates may be confounded by differences in the characteristics of patients who received treatment. To address the confounding, we included patients' demographic characteristics and cancer stage as controls in the Cox model and measured survival in control arms only during the 5 years before the treatment arm regimen's approval. This eliminates the possibility that patients self-select into the control arm of our analysis. Second, our sample is limited to Medicare patients diagnosed with one of five tumor types and for treatments that were FDA-approved before 2009, which limits the generalizability of the results. Although the study sample was not representative of the entire US population with cancer, it was representative of Medicare patients with breast, colorectal, lung, ovarian, or pancreatic cancer. Third, our ability to match our baseline sample to RCT inclusion and exclusion criteria was imperfect because SEER-Medicare does not contain patient genotype information and the SEER-Medicare data set largely contains individuals aged 65 years and older. Fourth, treatments may be administered differently in clinical trial and real-world settings; although physicians may treat patients beyond disease progression in the real world, in many RCTs a well-defined disease progression requires treatment to stop. Fifth, we found mixed evidence on whether the proportional hazards assumptions are violated as in some specifications the HR increases over time. Nevertheless, the magnitude of the time-varying component of the treatment is not large over reasonable follow-up times (i.e., 2-3 years). Furthermore, it is not unlikely that an RCT becomes less informative as the follow-up time increases. More generally, this finding suggests that extrapolating our adjustment factor estimate beyond the maximal followup periods of these studies (i.e., about 2-3 years) should be done with great caution. Fifth, to ensure a sufficient sample size for our analysis we did not separately measure the percentage difference ƒ for PFS and TTP, but future research should examine the relationship between efficacy and effectiveness separately using various RCT surrogate endpoints. Finally, both treatment efficacy and effectiveness may vary by patient subgroup; we, however, did not examine this in the present study. Future research should consider using ClinicalTrials.gov data to conduct a similar exercise on patient subgroups.
Conclusions
On the basis of the evidence from 21 RCTs of treatments across five tumor types, on average real-world OS was comparable with OS benefits estimated in RCTs. Nevertheless, it was approximately 16% lower than RCT efficacy measured on the basis of surrogate endpoints in the five tumors studied. These results, however, varied by tumor type, line of therapy, trial size, and trial location (US vs. non-US). These findings provide an empirical basis upon which to translate surrogate endpoint evidence from RCTs into meaningful and evidence-based assessments of realworld effectiveness. Our analysis not only points toward future refinements of the ASCO framework but also demonstrates a general methodology for predicting real-world effectiveness that can be applied to rapidly growing sources of real-world oncology data. Lower score differences indicate that the empirically based framework is less favorable to the treatment arm of a trial than using the ASCO framework; higher score differences represent the reverse. ASCO, American Society of Clinical Oncology; SHR, surrogate hazard ratio.
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